TY - JOUR
T1 - Alleviation of diabetic nephropathy by zinc oxide nanoparticles in streptozotocin‐induced type 1 diabetes in rats
AU - Alomari, Ghada
AU - Al‐trad, Bahaa
AU - Hamdan, Salehhuddin
AU - Aljabali, Alaa A. A.
AU - Al Zoubi, Mazhar Salim
AU - Al‐batanyeh, Khalid
AU - Qar, Janti
AU - Eaton, Gregory J.
AU - Alkaraki, Almuthanna K.
AU - Alshaer, Walhan
AU - Haifawi, Saja
AU - Jemon, Khairunadwa
AU - Chellappan, Dinesh Kumar
AU - Dua, Kamal
AU - Tambuwala, Murtaza M.
N1 - Funding Information:
The Deanship of Scientific Research and Graduate Studies at the University of Yarmouk funded this work (Grant number 34/2017). We sincerely thank Universiti Teknologi Malaysia for facilitating use of the transmission electron microscope unit.
Funding Information:
The Deanship of Scientific Research and Graduate Studies at the University of Yarmouk funded this work (Grant number 34/2017). We sincerely thank Universiti Teknologi Malaysia for facilitating use of the transmission electron microscope unit.
Publisher Copyright:
© 2021 The Authors. IET Nanobiotechnology published by John Wiley & Sons Ltd on behalf of The Institution of Engineering and Technology.
PY - 2021/7/1
Y1 - 2021/7/1
N2 - This study examines the effect of nanoparticles with zinc oxides (ZnONPs) on diabetic nephropathy, which is the primary cause of mortality for diabetic patients with end‐stage renal disease. Diabetes in adult male rats was induced via intraperitoneal injection of streptozotocin. ZnONPs were intraperitoneally administered to diabetic rats daily for 7 weeks. Diabetes was associated with increases in blood glucose level, 24‐h urinary albumin excretion rate, glomerular basement membrane thickness, renal oxidative stress markers, and renal mRNA or protein expression of transforming growth factor‐β1, fibronectin, collagen‐IV, tumour necrosis factor‐α and vascular endothelial growth factor‐A. Moreover, the expression of nephrin and podocin, and the mRNA expression of matrix metalloproteinase‐9 were decreased in the diabetic group. These changes were not detected in the control group and were significantly prevented by ZnONP treatment. These results provide evidence that ZnONPs ameliorate the renal damage induced in a diabetic rat model of nephropathy through improving renal functionality; inhibiting renal fibrosis, oxidative stress, inflammation and abnormal angiogenesis; and delaying the development of podocyte injury. The present findings may help design the clinical application of ZnONPs for protection against the development of diabetic nephropathy.
AB - This study examines the effect of nanoparticles with zinc oxides (ZnONPs) on diabetic nephropathy, which is the primary cause of mortality for diabetic patients with end‐stage renal disease. Diabetes in adult male rats was induced via intraperitoneal injection of streptozotocin. ZnONPs were intraperitoneally administered to diabetic rats daily for 7 weeks. Diabetes was associated with increases in blood glucose level, 24‐h urinary albumin excretion rate, glomerular basement membrane thickness, renal oxidative stress markers, and renal mRNA or protein expression of transforming growth factor‐β1, fibronectin, collagen‐IV, tumour necrosis factor‐α and vascular endothelial growth factor‐A. Moreover, the expression of nephrin and podocin, and the mRNA expression of matrix metalloproteinase‐9 were decreased in the diabetic group. These changes were not detected in the control group and were significantly prevented by ZnONP treatment. These results provide evidence that ZnONPs ameliorate the renal damage induced in a diabetic rat model of nephropathy through improving renal functionality; inhibiting renal fibrosis, oxidative stress, inflammation and abnormal angiogenesis; and delaying the development of podocyte injury. The present findings may help design the clinical application of ZnONPs for protection against the development of diabetic nephropathy.
KW - Biotechnology
KW - Electrical and Electronic Engineering
KW - Electronic, Optical and Magnetic Materials
UR - https://www.scopus.com/pages/publications/85107800146
UR - https://onlinelibrary.wiley.com/doi/10.1049/nbt2.12026
U2 - 10.1049/nbt2.12026
DO - 10.1049/nbt2.12026
M3 - Article
C2 - 34694755
SN - 1751-8741
VL - 15
SP - 473
EP - 483
JO - IET Nanobiotechnology
JF - IET Nanobiotechnology
IS - 5
ER -